Vertex Pharmaceuticals Incorporated
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Reshma Kewalramani
- Full Time Employees
- 6,100
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 50 Northern Avenue Boston MA United States of America 02210
- IPO Date
- Jul 24, 1991
- CIK
- 0000875320
- Website
- vrtx.com
- Similar Companies
- Business
- Vertex Pharmaceuticals Incorporated (VRTX), headquartered in Boston, Massachusetts and founded in 1989, develops, manufactures and commercializes transformative medicines for serious diseases, with a primary focus on cystic fibrosis, sickle cell disease, beta thalassemia and emerging areas including pain, kidney disease and type 1 diabetes; its portfolio features the CFTR modulators TRIKAFTA/KAFTRIO, ALYFTREK, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO, the CRISPR/Cas9 gene-edited therapy CASGEVY (co-developed with CRISPR Therapeutics), the non-opioid NaV1.7 pain treatment JOURNAVX/suzetrigine, and investigational assets such as povetacicept (for IgA nephropathy and other autoimmune kidney diseases), inaxaplin (for APOL1-mediated kidney disease), VX-407 (for autosomal dominant polycystic kidney disease), VX-522 (CFTR mRNA therapy with Moderna), VX-880/VX-264 (stem cell therapies for type 1 diabetes) and VX-993 (next-generation pain candidate); the company operates research facilities in San Diego, California and Milton Park, Oxfordshire, UK, with commercial presence across North America, Europe, Australia, Asia and the Middle East. In recent developments, Vertex completed its $4.9 billion acquisition of Alpine Immune Sciences in 2024 to secure povetacicept, entered an exclusive collaboration with Ono Pharmaceutical in June 2025 for povetacicept commercialization in Japan and South Korea (building on a prior deal with Zai Lab), launched ALYFTREK in the US and began European reimbursement efforts in England, Germany and Denmark, advanced CASGEVY and JOURNAVX launches with expanding US coverage including major PBMs and hospital networks, completed Phase 3 enrollment for povetacicept in IgA nephropathy (targeting accelerated US approval in H1 2026), initiated VX-407 Phase 2 proof-of-concept for ADPKD, progressed VX-522 Phase 1/2 data readout in H1 2025 and discontinued standalone development of an experimental pain drug following mid-stage failure while prioritizing suzertrigine/JOURNAVX expansion. Vertex reported Q3 2025 total revenues of $3.08 billion (up 11% year-over-year), driven by CF franchise growth, early new product contributions and favorable US pricing, with full-year 2025 guidance refined to $11.9-12.0 billion.
FDA Accepts Vertex's BLA for Povetacicept in IgA Nephropathy
Got $5,000? 1 Cash-Flow King to Buy and Hold Forever That Wall Street Is Completely Mispricing
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
These 2 Cheap Biotech Stocks Offer Potential for Low-Beta Growth
Vertex Pharmaceuticals Incorporated (VRTX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
VRTX's Alyftrek, Journavx & Casgevy See Strong Momentum in Q1 Earnings
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Vertex Pharmaceuticals Q1 Earnings Review: Pharma May Need Bolder M&A Strategy
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany
These Analysts Revise Their Forecasts On Vertex Pharmaceuticals After Q1 Earnings
CRISPR Therapeutics' Q1 Loss Wider Than Expected, Sales Miss Estimates
Breakfast News: PINS Mood Board Is Turning Bullish
Vertex Pharmaceuticals Incorporated (VRTX) Q1 2026 Earnings Call Transcript
Vertex (VRTX) Reports Q1 Earnings: What Key Metrics Have to Say
Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Beat Estimates
Vertex tops profit estimates as sales of new cystic fibrosis drug surge
Vertex Reports First Quarter 2026 Financial Results